These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 8391570

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: monotherapy.
    Skowron G.
    Hosp Pract (Off Ed); 1992 Aug; 27 Suppl 2():5-13. PubMed ID: 1324257
    [Abstract] [Full Text] [Related]

  • 4. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S, La Seta Catamancio S, Sheridan F, Parker D.
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [Abstract] [Full Text] [Related]

  • 5. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
    Lancet; 1999 Jun 12; 353(9169):2014-25. PubMed ID: 10376616
    [Abstract] [Full Text] [Related]

  • 6. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin JM, Tamalet C, Tedder R, Weber J, Weverling GJ.
    Lancet; 1997 Oct 04; 350(9083):983-90. PubMed ID: 9329513
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Effect of treatment with nucleoside analogues in subjects with primary genotypic resistance to zidovudine].
    Leal M, Caruz A, Rey C, Lissen E.
    Med Clin (Barc); 1996 Nov 30; 107(19):755. PubMed ID: 9082095
    [No Abstract] [Full Text] [Related]

  • 9. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
    Eron JJ, Chow YK, Caliendo AM, Videler J, Devore KM, Cooley TP, Liebman HA, Kaplan JC, Hirsch MS, D'Aquila RT.
    Antimicrob Agents Chemother; 1993 Jul 30; 37(7):1480-7. PubMed ID: 7689822
    [Abstract] [Full Text] [Related]

  • 10. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH.
    J Virol; 1996 Sep 30; 70(9):5922-9. PubMed ID: 8709213
    [Abstract] [Full Text] [Related]

  • 11. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
    Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF.
    J Infect Dis; 1996 Jun 30; 173(6):1354-66. PubMed ID: 8648207
    [Abstract] [Full Text] [Related]

  • 12. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.
    Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Brown AJ, Savara AV, Hazelwood JD, D'Aquila RT.
    J Infect Dis; 2000 Mar 18; 181(3):904-11. PubMed ID: 10720511
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
    Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R.
    J Infect Dis; 1994 Apr 18; 169(4):722-9. PubMed ID: 8133086
    [Abstract] [Full Text] [Related]

  • 18. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
    Henry K, Erice A, Tierney C, Balfour HH, Fischl MA, Kmack A, Liou SH, Kenton A, Hirsch MS, Phair J, Martinez A, Kahn JO.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec 01; 19(4):339-49. PubMed ID: 9833742
    [Abstract] [Full Text] [Related]

  • 19. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
    Reichman RC, Tejani N, Lambert JL, Strussenberg J, Bonnez W, Blumberg B, Epstein L, Dolin R.
    Antiviral Res; 1993 Apr 01; 20(4):267-77. PubMed ID: 8097906
    [Abstract] [Full Text] [Related]

  • 20. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V, Stürmer M, Staszewski S, Gröschel B, Hertogs K, de Béthune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA.
    AIDS; 1998 May 07; 12(7):705-12. PubMed ID: 9619801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.